Episode 66: A clot, a clot, I want it not – secondary prevention with antiplatelets
In episode 66, we embark on a journey of epic proportions; at least relative to our understanding. With the help of Peter Loewen, we outline the anti-platelet options in secondary prevention of heart disease. We discuss at length the use ASA and clopidogrel but also touch on additional agents like warfarin, dipyridamole and others. Where the evidence is clear, we create opacity and where it is gray, we go dark. Both Mike and Peter end up in a quagmire and James offers them help by throwing them a string of one-liners and a bottle of low-dose ASA.
Show Notes
Secondary prevention with antiplatelets
1) ATTC Meta-analysis – aspirin in primary and secondary resistance
2) CURE trial – clopidogrel added to aspirin
3) Anti-platelets in patients with a history of vascular disease or other predisposing condition – absolute benefit – 3.6% over 2 years (combined CVD events)
4) Low-dose aspirin – absolute benefit – around 3.3% combined CVD events and 1.5% mortality over 3 yrs
5) CHARISMA – Clopidogrel and aspirin vs aspirin
N Engl J Med 2006; 354:1706-17
6) Half of the benefit of clopidogrel occurs in the first month of use Clopidogrel for the treatment of adult patients following acute coronary syndrome
Therapeutics Initiative Review
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
